[{"orgOrder":0,"company":"Biofabri","sponsor":"TuBerculosis Vaccine Initiative | University of Cape Town | Institut Pasteur de Madagascar | Biomedical Research Center EPLS | Universidad de Zaragoza | University of Stellenbosch | University of KwaZulu | Wits Health Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Live-Attenuated Tuberculosis Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Biofabri \/ TuBerculosis Vaccine Initiative | University of Cape Town | Institut Pasteur de Madagascar | Biomedical Research Center EPLS | Universidad de Zaragoza | University of Stellenbosch | University of KwaZulu | Wits Health Consortium","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/ TuBerculosis Vaccine Initiative | University of Cape Town | Institut Pasteur de Madagascar | Biomedical Research Center EPLS | Universidad de Zaragoza | University of Stellenbosch | University of KwaZulu | Wits Health Consortium"},{"orgOrder":0,"company":"Biofabri","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"BCG Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Biofabri \/ Bharat Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/ Bharat Biotech"},{"orgOrder":0,"company":"Biofabri","sponsor":"IAVI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Biofabri \/ IAVI","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/ IAVI"},{"orgOrder":0,"company":"Biofabri","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Biofabri \/ Biofabri","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/ Biofabri"},{"orgOrder":0,"company":"Biofabri","sponsor":"IAVI","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Biofabri \/ IAVI","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/ IAVI"}]

Find Clinical Drug Pipeline Developments & Deals by Biofabri

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : MTBVAC is a live-attenuated vaccine candidate, derived from a human isolate of Mycobacterium tuberculosis. It is being evaluated to prevent active TB lung disease in adolescents and adults.

                          Product Name : MTBVAC

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          February 26, 2025

                          Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : IAVI

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Mtbvac, the spanish tuberculosis vaccine, the first live attenuated vaccine of Mycobacterium tuberculosis, which is under clinical development for the treatment of tuberculosis in adults.

                          Product Name : MTBVAC

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          March 24, 2024

                          Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : Bharat Biotech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Under the agreement, IAVI is supporting development, global regulatory strategy, resource mobilization, and access planning for the adolescent/adult tuberculosis (TB) vaccine candidate MTBVAC.

                          Product Name : MTBVAC

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          May 17, 2023

                          Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : IAVI

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          04

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : This agreement between BHARAT BIOTECH and BIOFABRI would guarantee the worldwide production and the supply of the future vaccine, MTBVAC in more than 70 countries with a high TB incidence, such as India, country with the highest TB burden in the world, w...

                          Product Name : MTBVAC

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          March 16, 2022

                          Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated,BCG Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Bharat Biotech

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          05

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Lead Product(s) : Live-Attenuated Tuberculosis Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase III

                          Sponsor : TuBerculosis Vaccine Initiative | University of Cape Town | Institut Pasteur de Madagascar | Biomedical Research Center EPLS | Universidad de Zaragoza | University of Stellenbosch | University of KwaZulu | Wits Health Consortium

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : MTBVAC

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          July 23, 2021

                          Lead Product(s) : Live-Attenuated Tuberculosis Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : TuBerculosis Vaccine Initiative | University of Cape Town | Institut Pasteur de Madagascar | Biomedical Research Center EPLS | Universidad de Zaragoza | University of Stellenbosch | University of KwaZulu | Wits Health Consortium

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Lead Product(s) : Bacillus Calmette-Guérin Vaccine

                          Therapeutic Area : Oncology

                          Study Phase : Phase II

                          Sponsor : Fundación Investigación en Urología

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          June 12, 2019

                          Lead Product(s) : Bacillus Calmette-Guérin Vaccine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Fundación Investigación en Urología

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Lead Product(s) : Live-Attenuated Tuberculosis Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase II

                          Sponsor : South African Tuberculosis Vaccine Initiative | Universidad de Zaragoza | TuBerculosis Vaccine Initiative

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : MTBVAC

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          May 24, 2018

                          Lead Product(s) : Live-Attenuated Tuberculosis Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : South African Tuberculosis Vaccine Initiative | Universidad de Zaragoza | TuBerculosis Vaccine Initiative

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Lead Product(s) : Live-Attenuated Tuberculosis Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase I/ Phase II

                          Sponsor : South African Tuberculosis Vaccine Initiative | TuBerculosis Vaccine Initiative | Triclinium Clinical Trial Project Management (Pty) Ltd. | Universidad de Zaragoza

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : MTBVAC

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          April 06, 2016

                          Lead Product(s) : Live-Attenuated Tuberculosis Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : South African Tuberculosis Vaccine Initiative | TuBerculosis Vaccine Initiative | Triclinium Clinical Trial Project Management (Pty) Ltd. | Universidad de Zaragoza

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Lead Product(s) : Live-Attenuated Mycobacterium Tuberculosis Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase I

                          Sponsor : Universidad de Zaragoza | Centre Hospitalier Universitaire Vaudois | TuBerculosis Vaccine Initiative

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : MTBVAC

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          December 17, 2013

                          Lead Product(s) : Live-Attenuated Mycobacterium Tuberculosis Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Universidad de Zaragoza | Centre Hospitalier Universitaire Vaudois | TuBerculosis Vaccine Initiative

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank